Trial Profile
Assessment of the immunogenicity and safety of the Northern Hemisphere 2010/2011-season influenza vaccine in elderly and young subjects according to European Medicines Agency (EMEA) regulations: an open label, non-randomised uncontrolled safety and efficacy study.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza A virus infections
- Focus Pharmacodynamics
- Sponsors Crucell
- 03 Mar 2011 New source identified and integrated (Clinicaltrials.gov, NCT01306305).
- 02 Feb 2011 New trial record